Blood Radiation Dose After 131I Therapy of Thyrotoxicosis

Green, M.; Fisher, Monica; Miller, H.; Wilson, G. M.

doi:10.1136/bmj.2.5246.210

Cited by 34 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…* Cases of leukaemia following treatment of cancer of the thyroid with 131I have been recorded (Pochln, 1964). The marrow dose, which is estimated to be of the order of 0.6-0-9 rads, is higher than the average dose estimated as 0.4 rads for most soft tissues (Ellett 1967;Green et al, 1961;Lewallen, 1963).…”

Section: Experimental Results With Animalsmentioning

confidence: 81%

The location and relative numbers of rediosensitive cells and of cells not considered to be rediosensitive in bone and in bone marrow

1967

Annals of the ICRP/ICRP Publication

View full text Add to dashboard Cite

show abstract

Section: Experimental Results With Animalsmentioning

confidence: 81%

The location and relative numbers of rediosensitive cells and of cells not considered to be rediosensitive in bone and in bone marrow

1967

Annals of the ICRP/ICRP Publication

View full text Add to dashboard Cite

show abstract

“…A high turnover of iodine is clinically significant because the decreased retention time of 131 I not only reduces the radiation dose delivered to the thyroid gland (target organ) that results in therapeutic failure but also results in increased radiation dose to non-target (blood and bone marrow) tissues [12,34,35]. It has been noted that up to 12-20% of GD patients may have a rapid 131 I turnover in the thyroid gland [13,36,37].…”

Section: Discussionmentioning

confidence: 99%

Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves’ Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis

Arora

Bal

2021

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose To compare 131 I-therapy outcomes in high turnover and normal turnover Graves' disease patients and predict optimal first 131 I activity for high turnover patients. Methods Retrospective cohort design (1:2) validated by propensity score analysis. Cohort 1, high turnover (2-h RAIU/24-h RAIU ≥ 1), n = 104, and cohort 2, normal turnover (ratio < 1), n = 208, patients were compared for post 131 I outcome. The cure was defined as a combined euthyroid and stable hypothyroid state following 131 I treatment. Logistic regression analysis was used for identifying prognostic factors. The propensity score was applied; 77 matched pairs (1:1 ratio) of high and normal turnover patients were selected as a validation set. Results First 131 I cure rates of 28% in high turnover and 66% in normal turnover groups (p = 0.001) were noted. The therapy cycles (median, 2 vs. 1) and cumulative 131 I activity (median, 15 vs. 7 mCi) were required to cure hyperthyroidism in cohort 1 and cohort 2, respectively. Age (> 44 years), higher grade of goitre, and 2-h RAIU (> 37%) were associated with 131 I therapy failure. The high turnover patients needed a factor of 1.5-2 times more 131 I activity to achieve a similar cure rate compared to the normal turnover patients. The first-dose cure rate was 31% vs. 60% by propensity score analysis (n = 154), no way different (28% vs.66%) from the whole group of 312 patients. Conclusion High turnover Graves' disease patients, if administered standard 131 I activity, the outcomes shall be poor. To improve the success rate, 131 I activity should be increased by 1.5 to 2 times in the high turnover patients.

show abstract

“…In the literature, there is no reported case of a malignancy with secondary and single doses given for the treatment of hyperthyroidism. However, the leukemia development was reported at high cumulative doses administered at multiple sessions [55][56][57].…”

Section: Side Effectsmentioning

confidence: 99%

Radioiodine Therapy of Benign Thyroid Diseases

Çayir¹

2017

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

Radioiodine-131 (I-131) is used in treatment of benign thyroid diseases with hyperthyroidism; toxic diffuse goiter, toxic nodular goiter and toxic multinodular goiter for long years. Treatment success depends on various factors. The most important factor affecting the success of treatment is the susceptibility to target tissue I-131. This review aims to give information about the physical and biological characteristics of I-131, advantages and disadvantages, indications and contraindications for I-131 therapy, patient preperation and administiration of I-131, dose selection, precautions on possible side effects, evaluation of treatment response and make an overview on the clinical studies about I-131 therapy.

show abstract

Blood Radiation Dose After 131I Therapy of Thyrotoxicosis

Cited by 34 publications

References 26 publications

The location and relative numbers of rediosensitive cells and of cells not considered to be rediosensitive in bone and in bone marrow

The location and relative numbers of rediosensitive cells and of cells not considered to be rediosensitive in bone and in bone marrow

Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves’ Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis

Radioiodine Therapy of Benign Thyroid Diseases

Contact Info

Product

Resources

About